Class summary at a glance.

Every drug in the Gonadotropin Releasing Hormone Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $923.5Mcombined across class
Total Rx claims: 342K68K unique beneficiaries
Generic mfrs (active): 12across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Relugolix

Brand: Orgovyx · 342K Part D claims (CY24) · 68K beneficiaries · First FDA approval: 2020-12-18

Brand-only (no generics) 323 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $923.5M

Class share

100%

of class CY24 spend

View profile →

Cetrorelix

Brand: Cetrorelix · — Part D claims (CY24) · First FDA approval: 2000-08-11

5 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ganirelix

Brand: Fyremadel · — Part D claims (CY24) · First FDA approval: 2021-06-01

7 generic mfrs

Low NADAC$62.35

→

Avg plan cost$62.35

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Relugolix, Estradiol Hemihydrate, and Norethindrone

Brand: Myfembree · — Part D claims (CY24) · First FDA approval: 2021-05-26

Brand-only (no generics) 40 plans require PA

Low NADAC$45.36

→

Avg plan cost$45.36

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.